How did Rafael Holdings' revenue and expenses trend in Q2 2025?

**Rafael Holdings' financial performance in Q2 2025 is not currently available**. The latest available data is from the first quarter of fiscal year 2025, which ended on October 31, 2024. According to the report:

1. **Financial Position on Q1 2025**: Rafael Holdings reported a net loss attributable to the company of $9.0 million for the three months ended October 31, 2024, compared to a net loss of $3.6 million in the same period of the previous year. The increase in losses was due to combined unrealized losses on the Company’s investment in Cyclo Therapeutics and in the convertible notes receivable from Cyclo.
2. **Cash Position**: As of October 31, 2024, Rafael Holdings had cash, cash equivalents, and marketable securities amounting to $54.3 million.
3. **Upcoming Events**: The company anticipated a shareholder vote on the merger agreement with Cyclo Therapeutics in the first calendar quarter of 2025, with plans to close promptly post shareholder approvals. The focus post-merger would be on Trappsol® Cyclo™, a potential market leader in treating Niemann-Pick Disease Type C1.

In conclusion, Rafael Holdings faced a net loss in Q1 2025, but had a stable cash position. The upcoming merger and focus on Trappsol® Cyclo™ suggest a strategic shift to consolidate assets and capitalize on promising clinical outcomes.